Eli Lilly的首席执行官说,英国的药品定价抑制创新,拖延病人的接触,警告投资损失和价格上涨。 Eli Lilly's CEO says UK drug pricing deters innovation and delays patient access, warning of investment losses and price hikes.

Elily CEO Dave Ricks将英国称为欧洲最糟糕的药品定价国家, 责怪严格的成本控制和退税制度, Eli Lilly CEO Dave Ricks labeled the UK the worst country in Europe for drug pricing, blaming strict cost controls and a rebate system that penalizes drug success for deterring investment and delaying patient access to new medicines. 他警告说,如果不进行改革,英国就有可能在创新和制药活动上失去价值,因为英国公司退出了Merck的伦敦研究停工和AstraZeneca停止投资等。 He warned that without reform, the UK risks losing out on innovations and pharmaceutical activity, citing company exits like Merck’s London research shutdown and AstraZeneca’s halted investment. Ricks注意到,由于价格差异,病人从巴黎前往购买Mounjaro,并强调英国价格可能上涨170%,Eli Lilly在变更前暂停装运。 Ricks noted patients travel from Paris to buy Mounjaro due to price differences and highlighted a potential 170% price increase in the UK, with Eli Lilly pausing shipments ahead of the change. 美国官员批评美国高昂的成本, 并提出国际差异, 可能会引发监管行动。 His comments come amid global debate over drug pricing, with U.S. officials criticizing high American costs and suggesting international disparities may prompt regulatory action. 英国政府说,它仍然致力于生命科学的发展,并愿意进行对话。 The UK government says it remains committed to life sciences growth and open to dialogue.